Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

States highlights: N.C. Medicaid overhaul; Conn. 'aid in dying' bill; Calif. Medical expenses crowdfunding

North Carolina health officials said Monday that their long-awaited proposal to overhaul how Medicaid operates in North Carolina is "realistic" and "achievable" and will make state budgets more predictable.

19 Mar 2014

Findings open way to identification of new cancer drugs to fight acute myeloid leukemia

The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.

18 Mar 2014

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).

18 Mar 2014

Researchers examine how diabetes drug can benefit cancer patients

For several years, a class of anti-diabetic drugs known as biguanides, has been associated with anti-cancer properties. A number of retrospective studies have shown that the widely used diabetes drug metformin can benefit some cancer patients.

18 Mar 2014

Merck Millipore announces joint development agreement with Sysmex Corporation

Merck Millipore, the Life Science division of Merck, today announced a clinical research, licensing and joint development agreement with Sysmex Corporation of Japan.

From Sysmex America, Inc. 18 Mar 2014

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant.

17 Mar 2014

Researcher discover new chemical class that attacks two key cancer cell building block targets

Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.

14 Mar 2014

Researchers examine mothers’ condition during maintenance period after child's treatment for ALL

"It's a whole new cancer world" and "I don't remember what it's like to have sleep" were the most common themes of mothers interviewed by University of Colorado Cancer Center researchers during the maintenance period after a child's treatment for acute lymphoblastic leukemia (ALL).

12 Mar 2014

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology.

10 Mar 2014

Researchers find that protein synthesis can be studied in adult stem cells

For the first time, researchers have shown that an essential biological process known as protein synthesis can be studied in adult stem cells - something scientists have long struggled to accomplish. The groundbreaking findings from the Children's Medical Center Research Institute at UT Southwestern (CRI) also demonstrate that the precise amount of protein produced by blood-forming stem cells is crucial to their function.

10 Mar 2014

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.

7 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

New poll: Democrats' advantage on health care, other issues not translating into election edge

In other political news, the conservative group Americans for Prosperity is pushing back against Democratic criticism of its recent health law attack ad by releasing another one.

5 Mar 2014

Ambit to provide overview of quizartinib drug candidate at Barclays Global Healthcare Conference

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014.

4 Mar 2014

First Edition: March 4, 2014

Today's headlines include highlights and themes from President Barack Obama's 2015 budget to be released today.

4 Mar 2014

Insurers gather new customers' health information -- a critical step in calculating prices for next year's plans offered on exchanges

Meanwhile, Reuters reports that chronically ill consumers who obtain coverage from the online insurance marketplaces may still face high drug costs despite the health law's ban on discriminatory insurance practices. Also, news outlets report on Time magazine's cover story that details how the Obama administration almost shutdown healthcare.gov during its early, fitful days.

3 Mar 2014

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).

3 Mar 2014

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

John F. DiPersio, M.D., Ph.D., will be recognized with the 19th Annual American Association for Cancer Research-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

3 Mar 2014

Senate majority leader blasts anti-Obamacare ads

The ads, released by the group Americans For Posterity, had Senate Majority Leader Harry Reid condemning them and the Koch brothers, the backers of the group, as "un-American" in a Senate floor speech Wednesday. He later softened his comments.

28 Feb 2014

UCLA develops experimental treatment that eliminates acute type of leukemia in mice

A diverse team of scientists from UCLA's Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects.

28 Feb 2014

Leukemia News and Research

Further Reading

States highlights: N.C. Medicaid overhaul; Conn. 'aid in dying' bill; Calif. Medical expenses crowdfunding

Findings open way to identification of new cancer drugs to fight acute myeloid leukemia

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Researchers examine how diabetes drug can benefit cancer patients

Merck Millipore announces joint development agreement with Sysmex Corporation

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Researcher discover new chemical class that attacks two key cancer cell building block targets

Researchers examine mothers’ condition during maintenance period after child's treatment for ALL

A pill may provide hope to relapsed leukemia and lymphoma patients

Researchers find that protein synthesis can be studied in adult stem cells

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

New poll: Democrats' advantage on health care, other issues not translating into election edge

Ambit to provide overview of quizartinib drug candidate at Barclays Global Healthcare Conference

First Edition: March 4, 2014

Insurers gather new customers' health information -- a critical step in calculating prices for next year's plans offered on exchanges

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

Senate majority leader blasts anti-Obamacare ads

UCLA develops experimental treatment that eliminates acute type of leukemia in mice

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News